Mode
Text Size
Log in / Sign up
Phase 2 Completed N=178 Randomized Double-blind Treatment

A Phase 2a Study to Evaluate EDP-938 in the Virus Challenge Model

RSV Infection
Source: ClinicalTrials.gov NCT03691623 ↗
Enrolled (actual)
178
Serious AEs
0.0%
Results posted
May 2022
Primary outcomePrimary: Area Under the Curve (AUC) of Respiratory Syncytial Virus (RSV) Viral Load — 134.70; 113.51; 624.30; 80.61 hours*log10 copies/milliliter (mL) — p=< 0.001

Summary

A randomised, Phase 2a, double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics and antiviral activity of multiple doses of orally administered EDP-938 in healthy subjects infected with RSV-A Memphis 37b. This study is designed to compare the antiviral effect of EDP-938 compared to a placebo control in the respiratory syncytial virus challenge model.

Outcome Measures

OutcomeResultp-value
PRIMARY
Area Under the Curve (AUC) of Respiratory Syncytial Virus (RSV) Viral Load
134.70; 113.51; 624.30; 80.61; 160.81; 808.28 < 0.001 sig
SECONDARY
Area Under the Curve (AUC) of Total Symptom Score
61.18; 37.36; 252.49; 26.70; 27.81; 232.53 < 0.001 sig
SECONDARY
Peak Total Symptom Score
2.3; 1.9; 4.9; 1.6; 1.8; 4.2 < 0.001 sig
SECONDARY
Total Symptom Score
0.9; 0.8; 1.9; 0.5; 0.3; 3.0
SECONDARY
Time to Peak Total Symptom Score
1.18; 1.76; 2.15; 1.45; 1.09; 1.94 = 0.199
SECONDARY
Time to Resolution From Peak Total Symptom Score
2.49; 2.83; 3.30; 2.19; 1.38; 5.17 = 0.145
SECONDARY
Total Weight of Nasal Mucus Produced
12.965; 7.428; 33.416; 2.983; 4.716; 22.391 < 0.001 sig
SECONDARY
Peak Viral Load
4.3552; 4.3111; 6.4727; 3.9718; 4.7727; 7.0973 < 0.001 sig
SECONDARY
Time to Peak Viral Load
0.74; 0.80; 2.59; 0.88; 0.79; 3.43 < 0.001 sig
SECONDARY
Time to Resolution From Peak Viral Load
2.03; 2.02; 4.03; 1.67; 1.63; 3.58 < 0.001 sig
SECONDARY
Time to Cessation of Virus Detection
3.5; 3.2; 8.5; 2.7; 2.5; 8.5 < 0.001 sig
SECONDARY
Safety and Tolerability as Assessed by Number of Participants With Treatment-emergent Adverse Events (TEAEs)
20; 21; 21; 8; 10; 11
SECONDARY
Maximum Plasma Concentration (Cmax) of EDP-938 and Its Metabolites
1370; 1151; 1237.91; 800.73; 1740; 1480
SECONDARY
Time to Maximum Plasma Concentration (Tmax) of EDP-938 and Its Metabolites
4.56; 5.00; 5.80; 6.07; 4.52; 4.10
SECONDARY
Terminal Phase Half-Life (t1/2) of EDP-938 and Its Metabolites
14.5; 13.8; 14.5; 13.7; 14.5; 13.4
SECONDARY
Apparent Systemic Clearance at Steady State (CLss/F) of EDP-938
26.9; 24.1; 21.3; 25.0
SECONDARY
Terminal Phase Rate Constant Calculated by Linear Regression of the Terminal Loglinear Portion of the Concentration vs. Time Curve (λz) of EDP-938 and Its Metabolites
0.05; 0.05; 0.05; 0.05; 0.05; 0.05
SECONDARY
Volume of Distribution at Steady State (Vss/F) of EDP-938
560; 476; 442; 491
SECONDARY
Plasma Concentration at 12 Hours (C12) of EDP-938 and Its Metabolites
679.35; 565.60; 822; 525; 168; 149
SECONDARY
Plasma Concentration at 24 Hours (C24) of EDP-938 and Its Metabolites
404; 453; 491; 287; 121; 136
SECONDARY
Area Under the Concentration Time Curve Time 0 to Time of Last Quantifiable Concentration (AUC0-last) of EDP-938 and Its Metabolites
16730; 7540; 16420; 5970; 32000; 27300
SECONDARY
Area Under the Plasma Concentration-Time Curve Over the Dosing Interval (AUC0-tau) of EDP-938 and Its Metabolites
22300; 12500; 14100; 8010; 5770; 3270
SECONDARY
Number of Participants With Correlation of Plasma Pharmacokinetic (PK) Area Under the Curve (AUC) and Viral Load AUC
0; 0; 0; 0
SECONDARY
Number of Participants With Correlation of Plasma Pharmacokinetic (PK) Area Under the Curve (AUC) and Total Symptom Score (TSS) AUC
0; 0; 0; 0

Eligibility Criteria

Inclusion Criteria

  • An informed consent document signed and dated by the subject
  • Age 18 to 55 years, inclusive
  • In good health with no history of major medical conditions
  • A total body weight ≥ 50 kg and Body Mass Index (BMI) ≥ 18 kg/m^2 and ≤ 30kg/m^2

Exclusion Criteria

  • Pregnant or nursing females
  • Acute or chronic medical illness
  • Abnormal lung function
  • Positive for human immunodeficiency virus (HIV), active hepatitis A, B or C test
  • Nose or nasopharynx abnormalities
  • Receipt of any investigational drug within 3 months prior to the planned date of viral challenge/first dose of study drug
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03691623). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search